Short answer
Medtronic (MDT) filed its Q1 2026 10-Q quarterly report on Feb 24, 2026 for the quarter ended Jan 23, 2026. Quarterly revenue was $9.0B (up 8.8% year over year) with net income of $1.1B.
Q1 2026 key financials · XBRL
- Revenue
- $9.0B
- +8.8% YoY · +0.6% QoQ
- Net income
- $1.1B
- −11.7% YoY · −16.8% QoQ
- Operating margin
- 16.2%
- EPS (diluted)
- $0.89
- −11.0% YoY · −16.0% QoQ
Source: XBRL data from the Medtronic (MDT) Q1 2026 10-Q on SEC EDGAR. USD.
Medtronic Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 FY2026 total net sales $9.0B, up ~9% YoY from $8.3B; nine-month sales $26.6B vs $24.6B prior year
- GAAP effective tax rate 18.1% vs 15.4% YoY; GAAP net income $1.14B vs $1.29B YoY; non-GAAP EPS $1.36 vs $1.39 YoY
- Best segment: Cardiovascular $3.5B, up 14% YoY; worst: Neuroscience $2.6B, up only 4% YoY
- Nine-month operating cash flow $4.76B vs $4.52B YoY; free cash flow $3.34B vs $3.12B; $1.1B cash plus $7.2B current investments on hand
- Key headwind: ~$185M pre-tax tariff impact estimated for FY2026; Diabetes separation pending within 18 months of May 2025 announcement
Risk Factors
- Section 'risk_factors' was empty or not found.
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Medtronic quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.